



CORRECTION

Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease

Cristian Guja · Juan P. Frías · Lisa Suchower · Elise Hardy ·
Galina Marr · C. David Sjöström · Serge A. Jabbour

Published online: October 4, 2020
© The Author(s) 2020

Correction to: Diabetes Ther
<https://doi.org/10.1007/s13300-020-00815-z>

In the original article, Table 1 was published with a type-set error. The correct Table 1 is given below.

The original article can be found online at <https://doi.org/10.1007/s13300-020-00815-z>.

C. Guja (✉)
“Carol Davila” University of Medicine and
Pharmacy, Bucharest, Romania
e-mail: cristian.guja@b.astral.ro

J. P. Frías
National Research Institute, Los Angeles, CA, USA

L. Suchower
Kelly Services, Gaithersburg, MD, USA

E. Hardy · G. Marr
AstraZeneca, Gaithersburg, MD, USA

C. D. Sjöström
AstraZeneca, Gothenburg, Sweden

S. A. Jabbour
Thomas Jefferson University, Philadelphia, PA, USA

Table 1 Demographics and baseline characteristics for participants with Type 2 diabetes, by baseline CKD category—8-study pool (intention-to-treat analysis set)

Characteristic	CKD3		CKD2	
	EQW N = 182	All comparators N = 207	EQW N = 772	All comparators N = 1043
Men, <i>n</i> (%)	105 (57.7)	105 (50.7)	419 (54.3)	608 (58.3)
Age (years), mean (SD)	62.5 (9.0)	62.2 (9.0)	56.9 (9.3)	56.9 (9.5)
Age < 65 years, <i>n</i> (%)	102 (56.0)	120 (58.0)	613 (79.4)	820 (78.6)
Race, White, <i>n</i> (%)	66 (36.3)	89 (43.0)	522 (67.6)	685 (65.7)
Race, Asian, <i>n</i> (%)	111 (61.0)	106 (51.2)	157 (20.3)	227 (21.8)
Race, Black or African American, <i>n</i> (%)	0	5 (2.4)	38 (4.9)	39 (3.7)
Body weight (kg), mean (SD)	76.9 (19.3)	78.5 (17.7)	88.8 (19.3) ^a	87.8 (19.1)
BMI (kg/m ²), mean (SD)	28.3 (5.1)	29.6 (5.8)	31.6 (5.5) ^a	31.4 (5.6)
BMI ≥ 35 (kg/m ²), <i>n</i> (%)	24 (13.2)	40 (19.3)	196 (25.4)	246 (23.6)
Sitting SBP (mm Hg), mean (SD)	133 (14.3)	136 (17.2)	131 (13.8)	131 (14.6)
Sitting DBP (mm Hg), mean (SD)	77 (9.7)	79 (9.6)	79 (9.3)	79 (8.8)
eGFR (mL/min/1.73 m ²), mean (SD)	52.7 (5.6)	53.3 (5.1)	75.9 (8.4)	75.9 (8.6)
uACR (mg/g), mean (SD), median	105 (348), 14.2 (<i>n</i> = 151)	116 (438), 20.4 (<i>n</i> = 165)	54.1 (171), 10.6 (<i>n</i> = 528)	47.9 (158), 10.6 (<i>n</i> = 810)
< 30 mg/g (normal), <i>n</i> (%)	96 (52.7)	108 (52.2)	398 (51.6)	609 (58.4)
≥ 30 to ≤ 300 mg/g (moderately increased albuminuria), <i>n</i> (%)	45 (24.7)	46 (22.2)	108 (14.0)	178 (17.1)
> 300 mg/g (severely increased albuminuria), <i>n</i> (%)	10 (5.5)	11 (5.3)	22 (2.8)	23 (2.2)
Unknown ^b , <i>n</i> (%)	31 (17.0)	42 (20.3)	244 (31.6)	233 (22.3)
Duration of T2D (years), mean (SD)	9.7 (6.8)	9.5 (6.8)	7.6 (6.3) ^a	6.3 (5.5) ^a
HbA _{1c} (%), mean (SD)	8.3 (0.8)	8.5 (0.9)	8.5 (1.1)	8.4 (1.1)
FPG (mg/dL), mean (SD)	168 (46.7) (<i>n</i> = 181)	176 (50.2) (<i>n</i> = 203)	172 (50.0) (<i>n</i> = 751)	171 (46.8) (<i>n</i> = 1026)
Baseline anti-hyperglycaemic drugs ^c				
None, <i>n</i> (%)	8 (4.4)	34 (16.4)	135 (17.5)	299 (28.7)
Metformin, <i>n</i> (%)	155 (85.2)	159 (72.5)	529 (68.5)	647 (62.0)
Sulfonylureas, <i>n</i> (%)	4 (2.2)	10 (4.8)	55 (7.1)	55 (5.3)

Table 1 continued

Characteristic	CKD3		CKD2	
	EQW N = 182	All comparators N = 207	EQW N = 772	All comparators N = 1043
Thiazolidinediones, n (%)	36 (19.8)	31 (15.0)	32 (4.1)	39 (3.7)
Insulin, n (%)	18 (9.9)	22 (10.6)	107 (13.9)	98 (9.4)

BMI body mass index, *CKD* chronic kidney disease, *CKD2* stage 2 CKD, *CKD3* stage 3 CKD, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *EQW* exenatide once weekly, *FPG* fasting plasma glucose, *HbA_{1c}* glycated haemoglobin, *N* number of participants in the pooled treatment group, *n* number of participants in analysis, *SBP* systolic blood pressure, *SD* standard deviation, *T2D* type 2 diabetes, *uACR* urinary albumin-to-creatinine ratio

^a One participant had no result

^b uACR was not collected in two studies (DURATION-7 and DURATION-8)

^c One additional participant took repaglinide (EQW, CKD2), which was not a permitted background anti-hyperglycaemic drug per the protocol

The original article has been corrected.

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and

indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.